We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

New ELISA-Type Immunologic Test Studies Seroprevalence Against SARS-CoV-2

By LabMedica International staff writers
Posted on 10 Feb 2021
Print article
Image: New ELISA-Type Immunologic Test Studies Seroprevalence Against SARS-CoV-2 (Photo courtesy of Polytechnic University of Valencia)
Image: New ELISA-Type Immunologic Test Studies Seroprevalence Against SARS-CoV-2 (Photo courtesy of Polytechnic University of Valencia)
A team of researchers has developed an affordable ELISA-type test that makes it possible to detect IgG and IgM antibodies against the SARS-CoV-2 virus from human serum.

The new ELISA-type immunologic test called DIFELISARS to study the seroprevalence against SARS-CoV-2 has been developed by researchers from the Polytechnic University of Valencia (Valencia, Spain) and is currently in the prototype phase. ELISA-type tests have been applied for decades in various fields of biomedical diagnosis, and they stand out due to their high sensitivity and reliability. Furthermore, they make it possible to analyze a high number of samples simultaneously - up to 120 samples in 180 minutes - which validates its suitability for broad population samplings such as seroprevalence studies.

The DIFELISARS test stands out due to its low cost compared to other existing tests on the market, as well as for its high sensitivity and reliability - classic characteristics of ELISA tests. The test provides a colorimetric signal, proportionate to the concentration of said antibodies, and makes it possible to characterize the sample by comparing positive and negative tests.

The researchers will now validate the test by analyzing a total 200 samples and will also study the differences in the immune response generated - antibody levels - among men and women from the analyzed serum samples. In the study, the team has already started gathering, preparing and characterizing approximately 50 serum samples from patients, which will be used as positive and negative COVID-19 tests. The samples taken will be increased until reaching the 200 needed to conduct the seroprevalence studies.

“The availability of a test of these attributes has now acquired critical importance, as it would allow easy, reliable and cheap monitoring of the individual response of each person during the current vaccination campaign,” said Ángel Montoya, director of the Immunotechnology line of the Ci2B at the Polytechnic University of Valencia.

“Although some ELISAs are currently on sale to detect antibodies against SARS-CoV-2 in human blood products, their price remains high and their real availability is scarce, because large amounts of institutions and governments around the world are trying to acquire them simultaneously in order to conduct their COVID-19 monitoring programs,” added Montoya. “We have worked on this project to tackle this, to get this low-cost test based on existing commercial immunoreactive products ready, which would help facilitate viral seroprevalence studies, while differentiating between sexes, in our immediate surroundings.”

Related Links:
Polytechnic University of Valencia

Gold Supplier
Coronavirus Array
Extended Coronavirus Array
COVID-19 Anitibody Test
SARS-CoV-2 Antibody Test
EliA SARS-CoV-2-Sp1 IgG test
SARS-CoV-2 Antigen Test
2019-nCoV Antigen Test (Lateral Flow Method)

Print article


Molecular Diagnostics

view channel
Image: Micrograph of a colorectal adenocarcinoma (Photo courtesy of Wikimedia Commons)

Plasma or Urine Liquid Biopsy Tests May Guide Colorectal Cancer Treatment

A recent paper suggested that liquid biopsy examination of blood or urine could aid in evaluating the effectiveness of therapy for colorectal cancers that had begun to metastasize beyond the site of the... Read more


view channel
Image: Sysmex CN-Series automated blood coagulation analyzer (Photo courtesy of Sysmex Corporation)

Siemens and Sysmex Extend Agreement to Provide One of the Largest Portfolios of Hemostasis Testing Systems and Reagents

Siemens Healthineers (Erlangen, Germany) and Sysmex Corporation (Kobe, Japan) have renewed their long-standing global supply, distributorship, sales and service agreement for a broad portfolio of hemostasis... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.